Tendon and ligament injuries are among the most career-threatening setbacks an athlete can face. Unlike muscle tissue, tendons have a notoriously poor blood supply, making natural healing slow and incomplete. BPC-157 (Body Protection Compound-157) has emerged as one of the most studied peptides for accelerating connective tissue repair.
The Tendon Healing Mechanism
BPC-157 promotes tendon healing through multiple pathways. It upregulates the expression of growth hormone receptors in tendon fibroblasts, making these cells more responsive to endogenous growth signals. It also stimulates the production of type I collagen — the primary structural protein in tendons — and promotes angiogenesis (new blood vessel formation) in the injured area, directly addressing the blood supply limitation that makes tendon healing so slow.
Clinical Evidence
Animal studies have demonstrated that BPC-157 administration significantly accelerates the healing of Achilles tendon transections, medial collateral ligament injuries, and rotator cuff tears. Treated animals showed superior tensile strength in healed tendons compared to controls, with histological analysis confirming more organized collagen fiber alignment.
WADA Status and Athletic Use
BPC-157 is currently classified as a prohibited substance by WADA under the S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) category. Athletes competing in tested sports should not use BPC-157 during the competitive season. However, it is commonly used during off-season rehabilitation periods under physician supervision.